Aspirin use for primary prevention in elderly patients

Area of Science:

• Cardiology
• Preventive Medicine
• Geriatrics

Background:

• Aspirin's role in primary prevention is debated due to a trade-off between reducing occlusive vascular events and increasing bleeding risks.
• The Anti Thrombotic Trialists (ATT) Collaboration meta-analysis (2009) indicated a 12% reduction in cardiovascular events with aspirin, primarily from decreased non-fatal myocardial infarctions.
• This cardiovascular benefit was nearly counterbalanced by an increase in major bleeding events.

Purpose of the Study:

• To evaluate the net clinical benefit of aspirin in primary cardiovascular prevention.
• To identify patient subgroups who may benefit most from aspirin therapy in primary prevention.
• To weigh the potential benefits of aspirin against its associated harms, particularly in older populations.

Main Methods:

• Meta-analysis of existing clinical trials (ATT Collaboration).
• Risk-benefit analysis considering both cardiovascular events and bleeding complications.
• Assessment of factors influencing the balance of aspirin's benefits and harms, including age and cardiovascular risk.

Main Results:

• Aspirin therapy showed a 12% reduction in cardiovascular events, mainly non-fatal myocardial infarctions.
• The reduction in cardiovascular events was largely offset by an increase in major gastro-intestinal and cerebral bleedings.
• The net benefit of aspirin varies individually, appearing more favorable in those with higher cardiovascular risk.

Conclusions:

• The net clinical benefit of aspirin for primary prevention is uncertain and requires careful individual assessment.
• Older individuals with higher cardiovascular risk, preserved function, low comorbidity, and low bleeding risk are most likely to benefit.
• Personalized risk-benefit analysis considering lifespan and functional status is crucial for guiding aspirin use in primary prevention.